Research Peptide Fundamentals, Checked at the Source

The short version

Right Peptides is a reference desk for claims, not a product catalogue. It brings four very different research records into the same view: KPV, semaglutide, CJC-1295, and NAD+. The point is not to rank them by popularity. It is to ask the same basic questions of each claim. What was studied? In what model or population? What endpoint changed? Which source supports the statement?

That method quickly reveals why broad labels can mislead. KPV has promising anti-inflammatory results, but chiefly in cells and animal models ^[1][2][3][4]. Semaglutide has large randomized human outcome trials ^[9][10][11]. CJC-1295 has small human studies showing biological activity, not a mature therapeutic evidence base ^[15][16][17]. NAD+ is not a peptide at all, and much of its human supplementation literature concerns precursors rather than NAD+ itself ^{[18][19][20][22]}. This desk keeps those distinctions visible. It offers research context, not personal medical advice or a recommendation to use any compound.

The three-part claim check

A research statement is only as useful as the path back to its evidence. Right Peptides uses a simple three-part check.

1. Model: Was the work done in a test tube, an animal model, a small pharmacology study, or a randomized human trial? A result in cultured intestinal cells can clarify a mechanism, but it cannot establish a human benefit.
2. Endpoint: Did investigators measure a signaling pathway, a laboratory marker, a patient-reported outcome, or a major clinical event? Moving a biomarker and preventing a clinical event are different achievements.
3. Source: Does the conclusion match the cited paper, including its population, comparator, and limits? A citation should make a claim inspectable rather than decorate it.

Applied consistently, this framework prevents a common error: carrying a precise finding into a broader setting where it has not been tested. KPV's PepT1 uptake and inflammatory-signaling findings came from cellular and mouse work ^[3]. Semaglutide's cardiovascular result came from a large defined human population with established cardiovascular disease ^[10]. CJC-1295's record establishes sustained GH and IGF-1 stimulation in healthy adults ^[16][17]. NAD+ precursor trials show changes in blood NAD+ or selected metabolic endpoints, while a current review finds clinical efficacy limited and tissue data sparse ^[18]. Each conclusion stays attached to its model and endpoint.

What are research peptides?

Peptides are short chains of amino acids. Some act as signals in the body; laboratory analogues may be designed to resist breakdown, bind a receptor longer, or test a biological pathway. The term research peptide can refer to a molecule studied only in laboratory settings, an investigational molecule tested in people, or a peptide that is also an approved prescription medicine. Those categories do not carry the same evidence or regulatory status.

This collection makes the category boundary visible. KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. CJC-1295 is a modified analogue of growth-hormone-releasing hormone. Semaglutide is a modified peptide medicine that activates the GLP-1 receptor. NAD+, by contrast, is a dinucleotide coenzyme, not a peptide; it appears here because it is often grouped into the same longevity and wellness research conversation. A careful digest should correct that taxonomy instead of repeating it.

The word research also does not mean that every commercial material has been clinically tested. Evidence about a defined compound in a controlled study does not automatically transfer to an unverified preparation. The compound pages therefore separate identity, mechanism, measured findings, reported experiences, safety, and regulatory context.

Four records, four levels of certainty

KPV leads this desk because it is a useful test of evidence discipline. Its literature supports anti-inflammatory mechanisms and delivery strategies in preclinical models, including targeted colitis formulations ^[1][2][3]. That is scientifically meaningful without being a clinical treatment claim.

Semaglutide sits at the clinical end of the spectrum. Large trials report defined weight, cardiovascular, and kidney outcomes in specified adult populations ^[9][10][11]. Its safety record is also far more developed, including gastrointestinal and biliary concerns described in a dedicated review ^[12].

CJC-1295 occupies the middle: human pharmacology studies show that it can produce sustained changes in growth hormone and IGF-1 while preserving pulsatile secretion ^[16][17], but the evidence is small and early. An analytical study also identified it in an unknown preparation from an anti-doping context, underscoring identity and provenance concerns ^[14].

NAD+ requires a category correction and an endpoint correction. It is a central cellular coenzyme ^[21]. Oral precursor trials show that NMN or NR can raise NAD+ measures and affect selected endpoints ^[19][20][22], but a current review concludes that human efficacy remains limited and tissue-specific evidence is sparse ^[18]. The comparison keeps all four records aligned without pretending they answer the same question.